This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0003319708321748v1 59/2_suppl/77S    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Toutouzas, P. Articles by Richter, D. Search for Related Content PubMed PubMed Citation Articles by Toutouzas, P. Articles by Richter, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Carotid Intima–Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial

Euroclinic Athens

^* To whom correspondence should be addressed. E-mail: richterdimitri{at}hotmail.com.

	Abstract

The ENHANCE trial was the first trial of ezetimibe– simvastatin with a surrogate marker as a primary endpoint. The combination of the 2 drugs is highly effective in reducing total cholesterol and low-density lipoprotein cholesterol levels and with a positive profile on high-density lipoprotein cholesterol. However, there are no data as yet about the clinical effectiveness of the addition of ezetimibe on statin therapy and whether this provides a further reduction of cardiovascular events. The answer to the clinical hard endpoints question will be provided in 2012 by the IMPROVE-IT trial comparing the effectiveness of simvastatin 40 mg plus ezetimibe versus simvastatin 40 mg on 18 000 acute coronary syndrome patients. The ENHANCE study failed in its primary endpoint, carotid intima–media thickness reduction, but has various methodological weaknesses that makes it very difficult to accept the American College of Cardiology statement that ezetimibe should be the last resort after trying all other available treatments.

First published on July 15, 2008, doi:10.1177/0003319708321748

Angiology 2008;59:77S.

A more recent version of this article appeared on August 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. S. Goumas LDL-Cholesterol is the King Angiology, June 1, 2009; 60(3): 387 - 388. [PDF]

				G. S. Goumas Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins? Angiology, February 1, 2009; 60(1): 93 - 98. [Abstract] [PDF]